Storys zum Thema Chemie

31.03.2008 – 17:19
Boehringer Ingelheim
Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Ingelheim, Germany (ots/PRNewswire) - - Results of 25,620 Patient Study ONTARGET(R) (ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial) Presented Today at the 57th Annual Scientific Session of the American College of Cardiology(1) - For Non-US Healthcare Media The results of the ...
mehr
26.03.2008 – 11:25
BASF SE
ots.Audio: BASF Podcast: The Chemical Reporter - What happens to film when it is developed?
Ludwigshafen (ots) - Nowadays, most of us have a digital camera. In this case you wouldn't even ask such a question. You just print out the pictures. Developing pictures through classic photography is a bit more complicated. In entertaining weekly episodes our Chemical Reporter answers ...
Ein Audio
mehr
19.03.2008 – 11:20
BASF SE
ots.Audio: BASF Podcast: The Chemical Reporter - What is chewing gum made of?
Ludwigshafen (ots) - You should be able to chew gum for some time without it dissolving. A determining factor is its chewable base. Nowadays, modern chewing gum consists mainly of a polymer mixture. In entertaining weekly episodes our Chemical Reporter answers questions of our Podcast ...
Ein Audio
mehr
12.03.2008 – 11:20
BASF SE
ots.Audio: BASF Podcast: The Chemical Reporter - What is dry ice?
Ludwigshafen (ots) - Dry ice cannot be found in nature. It is just not cold enough here on earth. In outer space, on the planet Mars for example, carbon dioxide hardens and turns into ice. But who is going to fly to Mars just to get dry ice? In entertaining weekly episodes our Chemical Reporter ...
Ein Audio
mehr
12.03.2008 – 11:20
BASF SE
ots.Audio: BASF Podcast - Better harvest in spite of climate stress
Ludwigshafen (ots) - In this Podcast you will learn about how plant biotechnology can help to make crops more tolerant against climate stress. Climatic conditions such as heat or cold and rain or drought can determine whether a harvest turns out well or badly. Because whenever these conditions are not optimal, plants also find themselves in a ...
Ein Audio
mehr
25.10.2007 – 14:09
Boehringer Ingelheim
New Three-Year Data Confirms Aptivus(R) (tipranavir) as Effective and Durable Treatment Option for Treatment-Experienced Patients
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
mehr
06.09.2007 – 09:05
Boehringer Ingelheim
Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992(i)
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
mehr
03.09.2007 – 10:04
Boehringer Ingelheim
Suffering in Silence - The Real Impact of the Last Taboo
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
mehr
25.07.2007 – 03:03
Boehringer Ingelheim
Data Presented at International AIDS Society (IAS) Conference Shows Long-Term Viramune(R) (nevirapine) Efficacy and Increase in Good Cholesterol
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
mehr
24.07.2007 – 08:05
Boehringer Ingelheim
Boehringer Ingelheim Announces First International Head-to-Head Trial of Aptivus(R) (tipranavir) versus darunavir in Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
mehr
23.07.2007 – 06:51
Boehringer Ingelheim
European Survey to Gain Insight into Treatment-Experienced Patients' Perspectives on Living with HIV
Sydney, Australia (ots/PRNewswire) - Recent launches of new protease inhibitors and the anticipated availability of new antiretroviral drug classes have increased the therapeutic options available to treatment-experienced HIV-positive patients, and made achieving an undetectable viral load a realistic goal ...
mehr
23.07.2007 – 03:45
Boehringer Ingelheim
International Experts and Women Living With HIV Discuss Urgent Needs of HIV-Positive Women at International AIDS Society (IAS) Congress
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
mehr
18.06.2007 – 10:05
Boehringer Ingelheim
New Study Shows That telmisartan has Greater Renoprotective Potential Than losartan in Hypertensive Patients With Type 2 Diabetes
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
mehr
18.06.2007 – 10:03
Boehringer Ingelheim
More Than Half of Hypertensive Patients Remain Uncontrolled and at Higher Risk of Heart Attack and Stroke - Telmisartan May Decrease This Risk
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media - Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension (ESH) show that measuring blood pressure in a doctor's office alone does ...
mehr
14.06.2007 – 14:11
Boehringer Ingelheim
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) in Diverse Group of Highly Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-1 infected patients. The trial ...
mehr
07.06.2007 – 18:20
Boehringer Ingelheim
Efficacy of Boehringer Ingelheim's Pramipexole (Mirapexin(R)/Sifrol(R) Also Demonstrated in Patients With Daytime RLS Symptoms
Ingelheim Am Rhein, Germany (ots/PRNewswire) - - Studies Reinforce the Benefits of Pramipexole From Daytime Symptom Control, Including Afternoon and Early Evening Onset - For Healthcare Media Outside the U.S.A. New data demonstrate that pramipexole (Mirapexin(R)/Sifrol(R)) is also efficacious and ...
mehr
10.05.2007 – 07:04
Boehringer Ingelheim
Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS Trial
Ingelheim, Germany (ots/PRNewswire) - - Trial to Compare Efficacy and Safety of Viramune(R) (Nevirapine) Versus Atazanavir/Ritonavir in Treatment-Naive Patients Boehringer Ingelheim GmbH announced today that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune(R) (nevirapine), ...
mehr
31.01.2007 – 09:10
Boehringer Ingelheim
Data Published in AIDS Show Viramune(R) (nevirapine) Achieves Durable Benefit in Switch Patients
Ingelheim, Germany (ots/PRNewswire) - Long-term data from the Nevirapine/Efavirenz/Abacavir (NEFA) study demonstrate that patients who switched from a protease inhibitor-based regimen to a non-nucleoside reverse transcriptase inhibitor-based regimen containing Viramune(R) (nevirapine) or efavirenz achieved comparable efficacy and safety to their previous regimen ...
mehr
15.11.2006 – 08:05
Boehringer Ingelheim
Long-Term Data Show Aptivus(R) (tipranavir) Continues to Outperform Group of Protease Inhibitors in RESIST Trials
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
mehr
10.11.2006 – 14:59
Boehringer Ingelheim
FDA Approves Boehringer Ingelheim's Pramipexole for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
mehr
31.10.2006 – 08:32
Boehringer Ingelheim
Boehringer Ingelheim's Pramipexole (Mirapexin(R)/Sifrol(R)) Shown to Improve Depressive and Motivational Symptoms in Parkinson's Disease
Kyoto, Japan (ots/PRNewswire) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease-Modification Trial - For non-US Healthcare Media New data presented today from a meta-analysis* of nearly 1,300 Parkinson's disease (PD) patients indicate that pramipexole (Mirapexin(R) ...
mehr
25.10.2006 – 12:17
Boehringer Ingelheim
Boehringer Ingelheim: Unfounded Fear of Addiction Prevents Laxative Use
Berlin, Germany (ots/PRNewswire) - - Global Survey Highlights Misunderstandings About Causes and Treatment of Constipation - Not for use or publication in the USA Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show ...
mehr
14.08.2006 – 17:04
Boehringer Ingelheim
Tipranavir Achieves Virologic and Immunologic Improvements in HIV-Positive Children at 48-Weeks of Therapy
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th International AIDS Conference (IAC) in Toronto, Canada. Results from this 48-week analysis show that patients achieved virologic ...
mehr
12.06.2006 – 12:38
BASF SE
BASF Completes Acquisition of Engelhard Corporation
Ludwigshafen, Germany (ots/PRNewswire) - - BASF CEO Hambrecht: 'We started the integration process.' BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the successful completion of its acquisition of Engelhard Corporation (NYSE: EC). "Together with the Engelhard team we have started the integration process in which our customers continue to be the key priority," ...
mehr
09.06.2006 – 12:52
BASF SE
BASF Receives Over 90% of Engelhard Shares
Ludwigshafen, Germany (ots/PRNewswire) - - BASF Announces Completion of Subsequent Offering Period BASF Aktiengesellschaft (Frankfurt: BAS; NYSE: BF [ADR]; LSE: BFA; SWX: AN) today announced the completion of the subsequent offering period for the outstanding shares of Engelhard. As of 8:00 p.m. New York City time on June 8, 2006, a total of 113,489,680 shares, representing more than 90% of Engelhard's (NYSE: ...
mehr
06.06.2006 – 12:18
BASF SE
BASF Receives Majority of Engelhard Shares
Ludwigshafen, Germany (ots/PRNewswire) - - BASF-CEO Hambrecht: 'Special day for BASF and Engelhard, more innovative solutions for customers.' - Subsequent offering period to expire on June 8, 2006 BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced the expiration of its initial tender offer period to purchase all of the outstanding shares of Engelhard Corporation ...
mehr
30.05.2006 – 14:41
BASF SE
BASF and Engelhard Reach Agreement
Ludwigshafen, Germany (ots/PRNewswire) - - Engelhard Recommends That Engelhard's Shareholders Accept BASF's Offer - BASF CEO Hambrecht: "Crucial step towards acquisition of Engelhard." BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) announced today that it signed a definitive agreement with Engelhard Corporation (NYSE: EC). According to the agreement, Engelhard will recommend that Engelhard shareholders tender their shares to BASF ...
mehr
24.05.2006 – 20:42
BASF SE
ISS Recommends That Engelhard's Shareholders Vote 'FOR' BASF's Nominees
Ludwigshafen, Germany (ots/PRNewswire) - BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced that Institutional Shareholder Services (ISS) has recommended that Engelhard's shareholders vote for BASF's five nominees for election to Engelhard's Board of Directors at the June 2 Annual Shareholders' Meeting. ISS is a ...
mehr
23.05.2006 – 17:06
Boehringer Ingelheim
New Data Shed Light on the Global Incidence of Constipation
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
mehr
22.05.2006 – 13:17
BASF SE
BASF Raises Offer to Engelhard Shareholders to US$39 Per Share
Ludwigshafen, Germany (ots/PRNewswire) - - BASF CEO Hambrecht: 'This is our last, best and final offer.' BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced that it has raised its all-cash offer for Engelhard Corporation (NYSE: EC) to US$39 per share from its previous offer of US$38 per share. "We are confident that Engelhard's shareholders will recognize the superior ...
mehr

Vorherige78910111213141516Nächste